- Email: [email protected]
Selected Phase II Clinical Trials in Lung Cancer
c linical trials Selected Phase II Clinical Trials in Lung Cancer Trial
Sponsor
Contact
Contact Information
Phase II Pilot Study of Cisplatin, Etoposide, and Cyclophosphamide in Patients with Extensive-Stage Small-Cell Lung Cancer
Other
Ronald Go, MD, Protocol Chair
608-775-2139; 800-362-9567 ext. 52385
Phase II Randomized Study of Tariquidar and Docetaxel in Patients with Recurrent or Metastatic Lung, Ovarian, or Cervical Cancer
NCI
Chaohong Fan, MD, PhD, Protocol Chair
301-402-4467; [email protected]
Phase II Pilot Study of Arsenic Trioxide in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Other
Dennie Jones, MD, Protocol Chair
409-772-1165
NCI
Gregory Otterson, MD, Protocol Chair
614-293-9316; 800-293-5066
Phase II Randomized Study of Carboplatin and Etoposide with or Without Oblimersen in Patients with Extensive-Stage Small-Cell Lung Cancer
NCI
Ravi Salgia, MD, PhD, Protocol Chair
773-702-4399; 888-824-0200; [email protected]. uchicago.edu
Phase II Study of CCI-779 in Patients with Stage IIIB (with Pleural Effusion) or IV Non–Small-Cell Lung Cancer
NCI
Alex Adjei, MD, PhD, Protocol Chair
507-284-2511; [email protected]
Phase II Study of Cisplatin, Irinotecan, and Bevacizumab in Patients with ExtensiveStage Small-Cell Lung Cancer
NCI
Neal Ready, MD, Protocol Chair
401-444-5391; [email protected]
Phase II Study of Sorafenib in Patients with Recurrent or Progressive Stage IV Non–Small-Cell Lung Cancer
NCI
Martin Gutierrez, MD, Protocol Chair
301-435-0591
NCI, Pharmaceutical/ Industry
Afshin Dowlati, MD, Protocol Chair
216-844-1228; 800-641-2422
NHLBI
Richard Childs, MD, Protocol Chair
301-594-8008; [email protected]
NCI
Heidi Gillenwater, MD, Principal Investigator
434-924-5226; 800-223-9173
Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy with a Vaccine Containing Interferon alfa– or Interferon gamma–Treated Tumor Cells Followed by Sargramostim (GM-CSF) in Patients with Advanced Cancer
Other
Charles Wiseman, MD, FACP, Protocol Chair
213-484-7575
Phase II Randomized Pilot Study of Recombinant Vaccinie-CEA-TRICOM Vaccine Followed by Recombinant Fowlpox-CEA-TRICOM Vaccine and Sargramostim (GM-CSF) with Versus Without Docetaxel in Patients with CEA-Expressing Metastatic Lung or Colorectal Cancer
NCI
John Marshall, MD, Protocol Chair
202-444-7064
Phase II Study of GVAX Lung Cancer Vaccine in Patients with Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma
NCI
Raja Mudad, MD, FACP, Study Coordinator
504-584-2967; 800-588-5300; muda001@mailhost. tcs.tulane.edu
Phase II Study of Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Patients with Limited-Stage Small-Cell Lung Cancer
NCI
Michael Kelley, MD, Protocol Chair
919-286-0411 ext. 7326
Phase II Study of Stereotactic Body Radiotherapy in Patients with Medically Inoperable Stage I or II Non–Small-Cell Lung Cancer
NCI
Robert Timmerman, MD, Principal Investigator
214-645-7637
Phase II Study of Neoadjuvant Induction Chemoradiotherapy Comprising Paclitaxel, Carboplatin, and High-Dose Radiotherapy Followed by Surgical Resection and Consolidative Chemotherapy Comprising Paclitaxel and Carboplatin in Patients with Stage IIIA or IIIB Non–Small-Cell Lung Cancer
NCI
Mohan Suntharalingam, MD, Protocol Chair
410-328-2331; 800-888-8823; [email protected]
Chemotherapy
Cell Cycle Inhibitors/Signal Transduction Phase II Study of FR901228 in Patients with Recurrent Small-Cell Lung Cancer
Monoclonal Antibodies/Small Molecules
Immunotherapy Phase II Study of Thalidomide in Patients with Extensive-Stage Small-Cell Lung Cancer Who Achieve a Complete or Partial Response to Induction Chemotherapy Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients with Refractory Metastatic Solid Tumors Phase II Study of Docetaxel and Thalidomide as Second-Line Therapy in Patients with Stage III or IV Non–Small-Cell Lung Cancer Vaccine Therapy
Radiation Therapy
224
Clinical Lung Cancer November 2005
Sponsor
Contact
Contact Information
Phase II Pilot Study of Cisplatin, Etoposide, and Cyclophosphamide in Patients with Extensive-Stage Small-Cell Lung Cancer
Other
Ronald Go, MD, Protocol Chair
608-775-2139; 800-362-9567 ext. 52385
Phase II Randomized Study of Tariquidar and Docetaxel in Patients with Recurrent or Metastatic Lung, Ovarian, or Cervical Cancer
NCI
Chaohong Fan, MD, PhD, Protocol Chair
301-402-4467; [email protected]
Phase II Pilot Study of Arsenic Trioxide in Patients with Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
Other
Dennie Jones, MD, Protocol Chair
409-772-1165
NCI
Gregory Otterson, MD, Protocol Chair
614-293-9316; 800-293-5066
Phase II Randomized Study of Carboplatin and Etoposide with or Without Oblimersen in Patients with Extensive-Stage Small-Cell Lung Cancer
NCI
Ravi Salgia, MD, PhD, Protocol Chair
773-702-4399; 888-824-0200; [email protected]. uchicago.edu
Phase II Study of CCI-779 in Patients with Stage IIIB (with Pleural Effusion) or IV Non–Small-Cell Lung Cancer
NCI
Alex Adjei, MD, PhD, Protocol Chair
507-284-2511; [email protected]
Phase II Study of Cisplatin, Irinotecan, and Bevacizumab in Patients with ExtensiveStage Small-Cell Lung Cancer
NCI
Neal Ready, MD, Protocol Chair
401-444-5391; [email protected]
Phase II Study of Sorafenib in Patients with Recurrent or Progressive Stage IV Non–Small-Cell Lung Cancer
NCI
Martin Gutierrez, MD, Protocol Chair
301-435-0591
NCI, Pharmaceutical/ Industry
Afshin Dowlati, MD, Protocol Chair
216-844-1228; 800-641-2422
NHLBI
Richard Childs, MD, Protocol Chair
301-594-8008; [email protected]
NCI
Heidi Gillenwater, MD, Principal Investigator
434-924-5226; 800-223-9173
Phase II Pilot Study of Cyclophosphamide and Active Intralymphatic Immunotherapy with a Vaccine Containing Interferon alfa– or Interferon gamma–Treated Tumor Cells Followed by Sargramostim (GM-CSF) in Patients with Advanced Cancer
Other
Charles Wiseman, MD, FACP, Protocol Chair
213-484-7575
Phase II Randomized Pilot Study of Recombinant Vaccinie-CEA-TRICOM Vaccine Followed by Recombinant Fowlpox-CEA-TRICOM Vaccine and Sargramostim (GM-CSF) with Versus Without Docetaxel in Patients with CEA-Expressing Metastatic Lung or Colorectal Cancer
NCI
John Marshall, MD, Protocol Chair
202-444-7064
Phase II Study of GVAX Lung Cancer Vaccine in Patients with Selected Stage IIIB or Stage IV Bronchoalveolar Carcinoma
NCI
Raja Mudad, MD, FACP, Study Coordinator
504-584-2967; 800-588-5300; muda001@mailhost. tcs.tulane.edu
Phase II Study of Cisplatin and Irinotecan Followed by Carboplatin, Etoposide, and Radiation Therapy in Patients with Limited-Stage Small-Cell Lung Cancer
NCI
Michael Kelley, MD, Protocol Chair
919-286-0411 ext. 7326
Phase II Study of Stereotactic Body Radiotherapy in Patients with Medically Inoperable Stage I or II Non–Small-Cell Lung Cancer
NCI
Robert Timmerman, MD, Principal Investigator
214-645-7637
Phase II Study of Neoadjuvant Induction Chemoradiotherapy Comprising Paclitaxel, Carboplatin, and High-Dose Radiotherapy Followed by Surgical Resection and Consolidative Chemotherapy Comprising Paclitaxel and Carboplatin in Patients with Stage IIIA or IIIB Non–Small-Cell Lung Cancer
NCI
Mohan Suntharalingam, MD, Protocol Chair
410-328-2331; 800-888-8823; [email protected]
Chemotherapy
Cell Cycle Inhibitors/Signal Transduction Phase II Study of FR901228 in Patients with Recurrent Small-Cell Lung Cancer
Monoclonal Antibodies/Small Molecules
Immunotherapy Phase II Study of Thalidomide in Patients with Extensive-Stage Small-Cell Lung Cancer Who Achieve a Complete or Partial Response to Induction Chemotherapy Phase II Study of Nonmyeloblative Allogeneic Peripheral Blood Stem Cell Transplantation and Donor Lymphocyte Infusions in Patients with Refractory Metastatic Solid Tumors Phase II Study of Docetaxel and Thalidomide as Second-Line Therapy in Patients with Stage III or IV Non–Small-Cell Lung Cancer Vaccine Therapy
Radiation Therapy
224
Clinical Lung Cancer November 2005